SK42899A3 - 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds - Google Patents

3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds Download PDF

Info

Publication number
SK42899A3
SK42899A3 SK428-99A SK42899A SK42899A3 SK 42899 A3 SK42899 A3 SK 42899A3 SK 42899 A SK42899 A SK 42899A SK 42899 A3 SK42899 A3 SK 42899A3
Authority
SK
Slovakia
Prior art keywords
substituted
alkoxyisoxazol
alkyl
acid derivatives
hydrogen
Prior art date
Application number
SK428-99A
Other languages
English (en)
Slovak (sk)
Inventor
Benny Bang-Andersen
Klaus P Bogeso
Povl Krogsgaard-Larsen
Lenz S Moltzen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SK42899A3 publication Critical patent/SK42899A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK428-99A 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds SK42899A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK109296 1996-10-04
PCT/DK1997/000426 WO1998015542A1 (en) 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Publications (1)

Publication Number Publication Date
SK42899A3 true SK42899A3 (en) 1999-08-06

Family

ID=8100908

Family Applications (1)

Application Number Title Priority Date Filing Date
SK428-99A SK42899A3 (en) 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Country Status (26)

Country Link
US (1) US6200999B1 (es)
EP (1) EP0934286B1 (es)
JP (1) JP2001501630A (es)
KR (1) KR20000048908A (es)
CN (1) CN1238766A (es)
AR (1) AR008880A1 (es)
AT (1) ATE230734T1 (es)
AU (1) AU733004B2 (es)
BG (1) BG103348A (es)
BR (1) BR9712198A (es)
CA (1) CA2268028C (es)
CZ (1) CZ116899A3 (es)
DE (1) DE69718338T2 (es)
EA (1) EA001625B1 (es)
ES (1) ES2189978T3 (es)
HU (1) HUP0000084A3 (es)
IL (1) IL129135A0 (es)
IS (1) IS5009A (es)
NO (1) NO312961B1 (es)
NZ (1) NZ334798A (es)
PL (1) PL332553A1 (es)
SK (1) SK42899A3 (es)
TR (1) TR199900724T2 (es)
UA (1) UA52698C2 (es)
WO (1) WO1998015542A1 (es)
ZA (1) ZA978877B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
ATE335737T1 (de) * 2000-09-15 2006-09-15 Vertex Pharma Isoxazole und ihre verwendung als erk-inhibitoren
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
MXPA05010760A (es) 2003-04-09 2005-12-12 Wyeth Corp Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
GT200400213A (es) 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
AU2006301376A1 (en) * 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
WO2009092324A1 (en) * 2008-01-16 2009-07-30 Hong Kong University Of Science And Technology Oxazolidine derivatives as nmda antagonists
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
WO2017126197A1 (ja) * 2016-01-21 2017-07-27 アグロカネショウ株式会社 2-アミノニコチン酸ベンジルエステル誘導体の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0456519T3 (da) 1990-05-11 1994-11-07 Sankyo Co Piperidyloxy- og quinuclidinyloxyisoxazolderivater, deres fremstilling og deres terapeutiske anvendelse
JPH08502508A (ja) 1992-10-23 1996-03-19 メルク シヤープ エンド ドーム リミテツド ドーパミンレセプターサブタイプリガンド
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds

Also Published As

Publication number Publication date
WO1998015542A1 (en) 1998-04-16
ATE230734T1 (de) 2003-01-15
AR008880A1 (es) 2000-02-23
EP0934286A1 (en) 1999-08-11
EA199900358A1 (ru) 1999-10-28
NZ334798A (en) 2000-06-23
NO991561D0 (no) 1999-03-30
CN1238766A (zh) 1999-12-15
HUP0000084A3 (en) 2001-12-28
HUP0000084A2 (hu) 2000-06-28
DE69718338D1 (de) 2003-02-13
EP0934286B1 (en) 2003-01-08
CA2268028A1 (en) 1998-04-16
UA52698C2 (uk) 2003-01-15
NO312961B1 (no) 2002-07-22
US6200999B1 (en) 2001-03-13
AU4451797A (en) 1998-05-05
CZ116899A3 (cs) 1999-09-15
TR199900724T2 (xx) 1999-06-21
AU733004B2 (en) 2001-05-03
BG103348A (en) 1999-11-30
DE69718338T2 (de) 2003-10-16
NO991561L (no) 1999-06-04
IL129135A0 (en) 2000-02-17
KR20000048908A (ko) 2000-07-25
ES2189978T3 (es) 2003-07-16
BR9712198A (pt) 1999-08-31
EA001625B1 (ru) 2001-06-25
PL332553A1 (en) 1999-09-13
ZA978877B (en) 1998-04-17
CA2268028C (en) 2003-03-18
IS5009A (is) 1999-03-23
JP2001501630A (ja) 2001-02-06

Similar Documents

Publication Publication Date Title
JP4430941B2 (ja) Edg受容体作動薬
JPH11509175A (ja) N−ヘテロアリールピリジンスルホンアミド誘導体およびエンドテリンアンタゴニストとしてのそれらの使用
USRE38200E1 (en) Indole-2,3-dione-3-oxime derivatives
KR20210024574A (ko) 세포 괴사 억제제 및 이의 제조 방법과 용도
SK42899A3 (en) 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds
JPH04234857A (ja) 3,5−ジ置換2−イソキサゾリンおよびイソキサゾール、それらの製法およびそれらを含有する薬学的組成物
AU2001264116B2 (en) Amidine derivatives as selective antagonists of NMDA receptors
US11149018B2 (en) Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
EP1167369A1 (en) Novel thiazolobenzimidazole derivatives
US10117864B2 (en) Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
US6239128B1 (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
RU2138488C1 (ru) Соединения 2-аминокарбоновой кислоты, замещенной 5-арилизоксазол-4-илом, и фармацевтическая композиция на их основе
JP2650739B2 (ja) 分割化アミノピロリジン神経防護剤
US11136296B2 (en) Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
WO2017153231A1 (de) Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
JP2837318B2 (ja) アンジオテンシンii拮抗性ピリジン誘導体